European EGPA Experts Share Latest Research Advances at Paris Conference
On September 18th, 2025, leading EGPA specialists from across Europe gathered in Paris for the 10th meeting of the European EGPA Study Group. The research-focused conference, held at the historic Maison de l’Amérique Latine, brought together doctors and researchers to present and discuss the latest scientific developments in understanding and treating this rare autoimmune condition. A small number of patient representatives also attended this primarily medical meeting.
The spirit was great, even though the French doctors and patients were confronted with the really bad news that Fasenra will not be reimbursed in France (see our separate news article on this topic).
Looking Back and Moving Forward
The day began with a fascinating journey through EGPA’s medical history, presented by Professor Loïc Guillevin, one of the most respected experts in the field. His presentation helped attendees understand how far medical understanding has advanced in recognizing and treating what was once called Churg-Strauss syndrome.
Promising New Research
Several exciting scientific developments emerged from the conference that could directly benefit patients in the coming years. Researchers presented their work on creating a new way to measure disease activity specifically designed for EGPA patients. This tool could help doctors better track how well treatments are working and make more informed decisions about care.
Another significant research focus was on long-term follow-up care. Medical experts are developing comprehensive plans to monitor EGPA patients over many years, ensuring that any changes in the condition are caught early and managed effectively.
Updates on Current Studies
The MAINRITSEG trial provided encouraging updates about maintaining remission in EGPA patients. This research is comparing two different medications – rituximab and azathioprine – to see which works better at keeping the disease under control once patients achieve remission.
New Treatment Options on the Horizon
There was also attention for early-stage activities around possible applications of products like tezepelumab and dupilumab in EGPA.
Patient Representation
While the meeting was primarily focused on medical research, patient perspectives were included through dedicated sessions on quality of life and patient-reported outcomes.
The boardmembers of the Italian patientgroup APACS launched the idea to develop a European-wide EGPA patient group. They did so giving a brief presentation together with VASAS from Switzerland and France Vascularites with the backup and support of Vasculitis International. Unfortunately, there was no time to discuss this idea with the EESG doctors.
a better future for EGPA patients
This scientific meeting demonstrates the continued commitment of medical experts to advance EGPA research, offering hope for improved treatments and better quality of life for patients across Europe.